European Journal of Clinical Pharmacology

, Volume 63, Issue 5, pp 499–503 | Cite as

Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study

  • Jacob Sode
  • Niels Obel
  • Jesper Hallas
  • Annmarie LassenEmail author
Pharmacoepidemiology and Prescription



Several case-control studies have reported that the use of fluoroquinolone increases the risk of rupture of the Achilles tendon. Our aim was to estimate this risk by means of a population-based cohort approach.


Data on Achilles tendon ruptures and fluoroquinolone use were retrieved from three population-based databases that include information on residents of Funen County (population: 470,000) in primary and secondary care during the period 1991–1999. A study cohort of all 28,262 first-time users of fluoroquinolone and all incident cases of Achilles tendon ruptures were identified.

Main outcome measures

The incidence rate of Achilles tendon ruptures among users and non-users of fluoroquinolones and the standardised incidence rate ratio associating fluoroquinolon use with Achilles tendon rupture were the main outcome measures.


Between 1991 and 2002 the incidence of Achilles tendon rupture increased from 22.1 to 32.6/100,000 person-years. Between 1991 and 1999 the incidence of fluoroquinolone users was 722/100,000 person-years, with no apparent trend over time. Within 90 days of their first use of fluoroquinolone, five individuals had a rupture of the Achilles tendon; the expected number was 1.6, yielding an age- and sex-standardised incidence ratio of 3.1 [(95% confidence interval (95%CI): 1.0–7.3). The 90-day cumulative incidence of Achilles tendon ruptures among fluoroquinolone users was 17.7/100,000 (95%CI: 5.7–41.3), which is an increase of 12.0/100,000 (95%CI: 0.0–35.6) compared to the background population.


Fluoroquinolone use triples the risk of Achilles tendon rupture, but the incidence among users is low.


Achilles tendon Antibiotics Cohort study Incidence Quinolone 



confidence interval


  1. 1.
    Jarvinen TA, Kannus P, Paavola M et al (2001) Achilles tendon injuries. Curr Opin Rheumatol 13(2):150–155PubMedCrossRefGoogle Scholar
  2. 2.
    Jarvinen TA, Kannus P, Maffulli N et al (2005) Achilles tendon disorders: etiology and epidemiology. Foot Ankle Clin 10(2):255–266PubMedCrossRefGoogle Scholar
  3. 3.
    Leppilahti J, Puranen J, Orava S (1996) Incidence of Achilles tendon rupture. Acta Orthop Scand 67(3):277–279PubMedCrossRefGoogle Scholar
  4. 4.
    Maffulli N, Waterston SW, Squair J et al (1999) Changing incidence of Achilles tendon rupture in Scotland: a 15-year study. Clin J Sport Med 9(3):157–160PubMedCrossRefGoogle Scholar
  5. 5.
    Houshian S, Tscherning T, Riegels-Nielsen P (1998) The epidemiology of Achilles tendon rupture in a Danish county. Injury 29(9):651–654PubMedCrossRefGoogle Scholar
  6. 6.
    Levi N (1997) The incidence of Achilles tendon rupture in Copenhagen. Injury 28(4):311–313PubMedCrossRefGoogle Scholar
  7. 7.
    Suchak AA, Bostick G, Reid D et al (2005) The incidence of Achilles tendon ruptures in Edmonton, Canada. Foot Ankle Int 26(11):932–936PubMedGoogle Scholar
  8. 8.
    Melhus A (2005) Fluoroquinolones and tendon disorders. Expert Opin Drug Saf 4(2):299–309PubMedCrossRefGoogle Scholar
  9. 9.
    Khaliq Y, Zhanel GG (2003) Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 36(11):1404–1410PubMedCrossRefGoogle Scholar
  10. 10.
    van der Linden PD, Sturkenboom MC, Herings RM et al (2002) Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 324(7349):1306–1307PubMedCrossRefGoogle Scholar
  11. 11.
    van der Linden PD, Sturkenboom MC, Herings RM et al (2003) Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 163(15):1801–1807PubMedCrossRefGoogle Scholar
  12. 12.
    van der Linden PD, van de LJ, Nab HW et al (1999) Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 48(3):433–437PubMedCrossRefGoogle Scholar
  13. 13.
    Shakibaei M, Pfister K, Schwabe R et al (2000) Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. Antimicrob Agents Chemother 44(2):261–266PubMedCrossRefGoogle Scholar
  14. 14.
    Shakibaei M, de Souza P, van Sickle D et al (2001) Biochemical changes in Achilles tendon from juvenile dogs after treatment with ciprofloxacin or feeding a magnesium-deficient diet. Arch Toxicol 75(6):369–374PubMedCrossRefGoogle Scholar
  15. 15.
    Frank L (2000) Epidemiology. When an entire country is a cohort. Science 287(5462):2398–2399PubMedCrossRefGoogle Scholar
  16. 16.
    Gaist D, Sorensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44(4):445–448PubMedGoogle Scholar
  17. 17.
    Rotmann KJ (2006) Epidemiology – an introduction. Oxford Press, OxfordGoogle Scholar
  18. 18.
    Maclure M (1991) The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 133(2):144–153PubMedGoogle Scholar
  19. 19.
    van der Linden PD, Nab HW, Simonian S et al (2001) Fluoroquinolone use and the change in incidence of tendon ruptures in the Netherlands. Pharm World Sci 23(3):89–92PubMedCrossRefGoogle Scholar
  20. 20.
    Goossens H, Ferech M, Vander SR et al (2005) Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365(9459):579–587PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Jacob Sode
    • 1
  • Niels Obel
    • 1
  • Jesper Hallas
    • 2
  • Annmarie Lassen
    • 1
    Email author
  1. 1.Department of Infectious MedicineOdense University HospitalOdense CDenmark
  2. 2.Clinical Pharmacology, Institute of Clinical PharmacologyUniversity of Southern DenmarkOdenseDenmark

Personalised recommendations